<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01419457</url>
  </required_header>
  <id_info>
    <org_study_id>T705aUS109</org_study_id>
    <nct_id>NCT01419457</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Favipiravir in Volunteers With Hepatic Impairment</brief_title>
  <official_title>A Phase I, Open-Label, Parallel-Group, Multiple-Dose Study to Determine the Pharmacokinetics of Favipiravir in Volunteers With Hepatic Impairment and in Healthy Control Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MDVI, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MDVI, LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to determine the pharmacokinetics of favipiravir in volunteers with
      hepatic impairment and in healthy control volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">February 2013</completion_date>
  <primary_completion_date type="Actual">February 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax of favipiravir</measure>
    <time_frame>predose and 0.25, 0.5, 0.75, 1, 2, 4, 6, 12, 18, 24, 36, 48 hours post-dose on Day 1 and Day 5</time_frame>
    <description>The PK parameters for favipiravir and its metabolite in hepatically impaired adult subjects relative to healthy adult subjects matched for age, weight, gender, and race status on Day 1 and on Day 5.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC of favipiravir</measure>
    <time_frame>predose and 0.25, 0.5, 0.75, 1, 2, 4, 6, 12, 18, 24, 36, 48 hours post-dose on Day 1 and Day 5</time_frame>
    <description>The PK parameters for favipiravir and its metabolite in hepatically impaired adult subjects relative to healthy adult subjects matched for age, weight, gender, and race status on Day 1 and on Day 5.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>vital signs</measure>
    <time_frame>13 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>electrocardiograms [ECGs]</measure>
    <time_frame>13 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>clinical laboratory assessment</measure>
    <time_frame>13 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse events [AEs]</measure>
    <time_frame>13 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>physical examination</measure>
    <time_frame>13 days</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Healthy</condition>
  <condition>Hepatic Impairment</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Normal hepatic function</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mild hepatic impairment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Moderate hepatic impairment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Severe hepatic impairment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Favipiravir</intervention_name>
    <description>1200 mg BID for Day 1 + 800 mg BID for Day 2-5</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <other_name>T-705a</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Favipiravir</intervention_name>
    <description>800 mg BID for Day 1 + 400 mg BID for Day 2-3</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
    <other_name>T-705a</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Favipiravir</intervention_name>
    <description>800 mg Single Dose</description>
    <arm_group_label>Group 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hepatically impaired groups:

               -  Agree to doctor approved birth control methods from Day 1 until 3 months
                  following the final dose of study drug.

               -  Have mild hepatic impairment (Child-Pugh Clinical Assessment Score Grade A, score
                  5 6) or moderate hepatic impairment (Child-Pugh Clinical Assessment Score Grade
                  B, score 7-9) or severe hepatic impairment (Child-Pugh Clinical Assessment Score
                  Grade C, score 10-15);

          -  Control group

               -  Agree to doctor approved birth control methods from Day 1 until 3 months
                  following the final dose of study drug.

               -  Healthy as determined by medical history, physical exam, vital signs, ECGs, and
                  clinical laboratory tests.

        Exclusion Criteria:

          -  Hepatically impaired groups:

               -  Have used any drugs known to significantly affect hepatic metabolism within 28
                  days, or is unable or unwilling to forgo the use of such products throughout the
                  study;

               -  Have any acute or unstable condition or disease, other than impaired hepatic
                  function, as determined by medical history, physical exam, ECG and clinical
                  laboratory tests;

               -  Known ongoing alcohol and/or drug abuse within 1 month

               -  Any evidence of progressive worsening liver function disease as indicated by
                  laboratory values;

               -  Have had an acute flare of hepatitis A or B within 6 months;

               -  Have acute, fulminant alcoholic hepatitis, determined either clinically or by
                  histology;

               -  Have a history of hepatoma or metastatic disease of the liver;

          -  Control group:

               -  Have used any drugs known to significantly affect hepatic metabolism within 28
                  days, or is unable or unwilling to forgo the use of such products throughout the
                  study;

               -  Have a history or presence of clinically cardiovascular, dermatologic, endocrine,
                  gastrointestinal, hematologic, hepatic, immunologic, neurologic, oncologic,
                  psychiatric, pulmonary, or renal disease or any other condition.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard A. Preston, MD/MSHP/MBA</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Miami</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orlando Clinical Research Center</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 10, 2011</study_first_submitted>
  <study_first_submitted_qc>August 17, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 18, 2011</study_first_posted>
  <last_update_submitted>October 20, 2015</last_update_submitted>
  <last_update_submitted_qc>October 20, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 22, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy</keyword>
  <keyword>hepatic impairment</keyword>
  <keyword>T-705a</keyword>
  <keyword>Favipiravir</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

